Kwangdong Pharmaceutical to Sell GSK Allergic Rhinitis Treatment 'Avamys'

Abamis Nasal Spray.

[Asia Economy Reporter Lee Gwan-joo] Kwangdong Pharmaceutical announced on the 27th that it has signed a sales partnership agreement with GlaxoSmithKline (GSK) for the allergy rhinitis treatment 'Avamys Nasal Spray' and has started distribution.

Avamys, introduced to Korea in 2009 after receiving approval as a prescription drug, is the top-selling intranasal steroid in the domestic market (based on IQVIA data). It is effective for treating symptoms of seasonal or perennial allergic rhinitis in adults and children aged 2 and older.

It primarily alleviates symptoms such as itchy or bloodshot eyes, runny nose, and nasal congestion caused by allergic rhinitis, and can be prescribed by medical professionals in various departments including otolaryngology, internal medicine, and pediatrics based on their judgment.

The main ingredient of Avamys sold by Kwangdong Pharmaceutical is 'Fluticasone Propionate (micronized) 0.05g,' available in a spray form for intranasal use with a capacity of 120 sprays. The improvement effect lasts for 24 hours after a single dose.

A Kwangdong Pharmaceutical official stated, “Since starting vaccine promotion and distribution cooperation with GSK in 2015, we have expanded our business relationship based on the high trust between the two companies. We hope to contribute to patients and medical professionals suffering from allergic rhinitis through Avamys, and expect this to be an opportunity to strengthen our respiratory sector in the future.”

This content was produced with the assistance of AI translation services.